Avalyn Pharma AVLN 深 滬
等待開盤 06-25 09:30:00 美东时间
30.09
-2.200
-6.81%
華盛通- 最 高33.22
- 今 開32.10
- 成交量 21.71万股
- 最 低 29.80
- 昨 收 32.29
- 總市值 13.34亿
- 52周最高 33.24
- 市盈率 靜 --
- 換手率 0.49%
- 52周最低 24.15
- 委 比 -71.00%
- 總股本 4433.31万
- 歷史最高 33.24
- 量 比 0.33
- 振 幅 10.59%
- 歷史最低 24.15
- 每 手 1
- 風險率 2.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Avalyn Pharma completed enrollment of 375 patients in the Phase 2b MIST trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis (PPF). The trial, designed to evaluate the safety and efficacy of two AP01 doses, is expected to report 12-month results in the second half of 2027. AP01 has shown promising safety and efficacy in earlier trials, with potential to improve lung function and quality of life for PPF patients.
06-17 12:00
Avalyn Pharma reports Q1 results
Avalyn Pharma press release (AVLN): Q1 net loss was $26.9 million for the first quarter of 2026, as compared to $17.5 million for the first quarter of 2025. Cash, cash equivalents, and marketable secu...
06-03 19:39
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma announced its Q1 2026 financial results, highlighting a successful IPO with $345M gross proceeds and $123.1M in cash as of March 31, 2026. The company is advancing three inhaled therapies for pulmonary fibrosis, with AP01's Phase 2b trial on track to complete enrollment mid-2026 and AP02's Phase 2 trial underway. Recent clinical data support favorable tolerability profiles. The company expects its current cash runway to sustain oper...
06-03 11:00
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
Avalyn Pharma To Present Updated Findings From ATLAS Open-Label Extension Trial Highlighting Long-Term Tolerability Profile Of AP01 For Treatment Of Pulmonary Fibrosis, At EULAR 2026
Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced an upcoming poster
05-21 20:03
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
Avalyn Pharma Inc. announced it will present updated findings from the ATLAS trial at EULAR 2026 in London, highlighting the long-term tolerability of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis. The presentation, titled "Nebulized pirfenidone (AP01) for progressive pulmonary fibrosis in connective tissue disease-associated and other interstitial lung diseases: 4-year data from the ATLAS open label extension trial," will take pl...
05-21 12:00
美股周涨跌榜 | 净回报超2600%！资管公司潘兴广场上市三日累涨超58%；慧荣科技周涨超52%
累计净回报超2600%！资管公司潘兴广场上市三日累涨超58%；慧荣科技周涨超52%，Q1营收同比翻倍大超预期>>
05-04 18:33
Lung disease drug developer Avalyn surges on public debut
Avalyn Pharma (AVLN), a biotech focused on developing inhaled therapeutics for the lung disorder pulmonary fibrosis, climbed ~55% on Thursday following an upsized initial public offering that raised t...
05-01 01:27
Avalyn Announces Pricing of Upsized Initial Public Offering
Avalyn Pharma Inc. announced the pricing of its upsized initial public offering of 16,666,667 shares at $18.00 per share, expecting to raise $300 million. The shares will begin trading on the Nasdaq Global Select Market on April 30, 2026, under the ticker "AVLN," with the offering closing on May 1, 2026. The company, focused on inhaled therapies for rare respiratory diseases, has granted underwriters a 30-day option to purchase an additional 2.5 ...
04-30 01:00
